Ly108/Slamf6 antibody | knockout validation | Merck MABF919

This is a knockout-validated antibody summary, based on the publication "SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Ly108/Slamf6 antibody | knockout validation | Merck MABF919 figure 1
Figure 1. Immunoblot analysis of expression of SLAMF6 WT and SLAMF6-/- splenocytes. From [1].
Antibody information

Rat monoclonal IgG2a

Company: Merck

Antibody: Ly108/Slamf6

Catalog number: MABF919

Summary: Rat monoclonal IgG2a against murine Ly108-human IgG1 Fc fusion protein. Reacts with mouse. Suitable for western blot, flow cytometry, immunoprecipitation and function assay.

Validation Method

Western blot

Sample

WT and SLAMF6-/- mouse splenocytes.

Blocking agent

1% milk solution.

Primary incubation

Overnight at 4°C

Secondary incubation

HRP-conjugated secondary antibodies for 1 hr at RT (Jackson ImmunoResearch Laboratories).

Detection

Enhanced chemiluminescence reagents (Clarity Western ECL Substrate, BioRad, Hercules, CA).

References
  1. Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, Ben David I, et al. SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. elife. 2020;9: pubmed publisher